Therefore, in this study, 1,449 FDA-approved drugs were screened to determine whether they could be used as therapeutic agents for the treatment of gastric cancer using growth inhibition assays of HAP1, HAP1 RNF43 KO, and HAP1 PWWP2B KO cells. The gene discussed is HAP1; the disease is gastric cancer.